ERBB2 and breast cancer: Brain metastases (BMS) are considerably more likely to occur in patients with HER2-positive advanced BC, and with the widespread use of HER2-targeted therapy, the prognosis of these patients has been greatly improved (Zimmer, Swearingen & Anders, 2020).